Bristol-Myers Squibb (BMY) PT Raised to $80 at UBS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- LCI Industries names interim CEO as Jason Lippert retires
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
Bristol-Myers Squibb Reports First Quarter Financial Results
April 28, 2016 6:59 AM EDTIncreases First Quarter Revenues 9% to $4.4 Billion Posts First Quarter GAAP EPS of $0.71 and Non-GAAP EPS of $0.74 Achieves Significant European Regulatory Milestones in Immuno-Oncology Opdivo Approved for Previously Treated Advanced Renal Cell Carcinoma Expanded Use of Opdivo to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer Positive Advisory Opinions for Opdivo + Yervoy Regimen and Empliciti Validation of Application for Opdivo in Classical Hodgkin Lymphoma... More
